Literature DB >> 28129628

Seroma indicates increased risk of lymphedema following breast cancer treatment: A retrospective cohort study.

Navid Mohamadpour Toyserkani1, Mads Gustaf Jørgensen2, Karen Haugaard3, Jens Ahm Sørensen2.   

Abstract

INTRODUCTION: Lymphedema is one of the most serious complications following breast cancer treatment. While many risk factors are well described the role of seroma formation has recently produced mixed results. Therefore, we aimed to evaluate if seroma is a risk factor for development of lymphedema in one of the largest retrospective cohort studies.
MATERIAL AND METHODS: We included all patients with unilateral breast cancer treated in the period of 2008-2014. Data regarding treatment and breast cancer characteristics were retrieved from the national breast cancer registry. Data regarding lymphedema treatment and seroma aspirations were retrieved from local treatment codes.
RESULTS: In total 1822 patients were included of which 291 developed lymphedema. Multivariate cox regression analysis showed that seroma was an independent risk factor (HR 1.92 CI 1.30-2.85, p= 0.001). Other independent risk factors were lymphadenectomy, radiation therapy, chemotherapy, BMI above 30, total lymph nodes removed above 15 and higher number of metastatic lymph nodes.
CONCLUSIONS: Postoperative seroma doubles the risk of developing lymphedema. Future studies should examine if seroma reducing measures will lead to lower risk of lymphedema.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Lymphedema; Postoperative complication; Rehabilitation; Seroma

Mesh:

Year:  2017        PMID: 28129628     DOI: 10.1016/j.breast.2017.01.009

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  7 in total

1.  The legacy of lymphedema: Impact on nursing practice and vascular access.

Authors:  Gail Larocque; Sheryl McDiarmid
Journal:  Can Oncol Nurs J       Date:  2019-07-01

2.  Adipose-derived regenerative cells and lipotransfer in alleviating breast cancer-related lymphedema: An open-label phase I trial with 4 years of follow-up.

Authors:  Mads Gustaf Jørgensen; Navid Mohamadpour Toyserkani; Charlotte Harken Jensen; Ditte Caroline Andersen; Søren Paludan Sheikh; Jens Ahm Sørensen
Journal:  Stem Cells Transl Med       Date:  2021-02-17       Impact factor: 6.940

3.  Tc-99m-Human Serum Albumin Transit Time as a Measure of Arm Breast Cancer-Related Lymphedema.

Authors:  Navid M Toyserkani; Svend Hvidsten; Siavosh Tabatabaeifar; Jane A Simonsen; Poul F Høilund-Carlsen; Jens A Sørensen
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-06-13

Review 4.  Omental Lymph Node Transfer for Lymphedema Patients: A Systematic Review.

Authors:  Antonio J Forte; Gabriela Cinotto; Daniel Boczar; Maria T Huayllani; Sarah A McLaughlin
Journal:  Cureus       Date:  2019-11-25

5.  Comparative Study Between Radioisotope Uptake and Fluorescence Intensity of Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer.

Authors:  Byeongju Kang; Jong Ho Lee; Jeeyeon Lee; Jin Hyang Jung; Wan Wook Kim; Gyoyeong Chu; Yeesoo Chae; Soo Jung Lee; In Hee Lee; Jung Dug Yang; Joon Seok Lee; Ho Yong Park
Journal:  J Breast Cancer       Date:  2022-06       Impact factor: 2.922

6.  Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention.

Authors:  Louise A Koelmeyer; Katrina Gaitatzis; Mary S Dietrich; Chirag S Shah; John Boyages; Sarah A McLaughlin; Bret Taback; Deonni P Stolldorf; Elisabeth Elder; T Michael Hughes; James R French; Nicholas Ngui; Jeremy M Hsu; Andrew Moore; Sheila H Ridner
Journal:  Cancer       Date:  2022-07-07       Impact factor: 6.921

7.  The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment.

Authors:  Mads G Jørgensen; Navid M Toyserkani; Frederik G Hansen; Anette Bygum; Jens A Sørensen
Journal:  NPJ Breast Cancer       Date:  2021-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.